The GEN-Y Biologics investment opportunity

The GEN-Y Biologics

investment opportunity

GEN-Y Biologics has an exciting pipeline of other development opportunities beyond the SARS-CoV-2 and dengue assets, but, the initial focus for investment is on the dengue portfolio.

Importantly, investors will benefit from the reassurance that GEN-Y Biologics is generating revenue from on-going ImTracker Multi sales and from the early introduction of the dengue Point of Care diagnostic arriving late 2022/early 2023.

The GEN-Y Biologics investment opportunity

GEN-Y Biologics has an exciting pipeline of other development opportunities beyond the SARS-CoV-2 and dengue assets, but, the initial focus for investment is on the dengue portfolio.

Importantly, investors will benefit from the reassurance that GEN-Y Biologics is generating revenue from on-going ImTracker Multi sales and from the early introduction of the dengue Point of Care diagnostic arriving late 2022/early 2023.

SARS-CoV-2 Pandemic and ImTracker MULTI – Product summary and strategic approach

For the investment perspective, virtually all the funding for this project has been made by the existing investors. Further investment is foreseen to be very small as GEN-Y Biologics implements the key strategies below

Providing clear insights into COVID risk

Key Strategies

The Dengue Portfolio – providing a new paradigm in care

The ability to be able to swiftly and accurately diagnose Dengue infection serotype in the field/clinical/hospital will be a huge advance in understanding individual dengue risk and circulating disease. Importantly, it will provide the platform for swift diagnosis and treatment with the dengue fully humanised antibody therapy.

Investors will take advantage of the >US$ 20M non-dilutive investment that has been spent in taking the project to its status today!

Dengue – The neglected tropical disease opportunity

The worldwide market opportunity for dengue treatment is huge – and today the financial cost as well as the human cost of dengue infection is high. For these reasons, The USA’s FDA and the EMA provide significant incentives for those achieving regulatory approval of treatments that can change the outcomes for patients. A great example is the US FDA’s Tropical Disease Priority Review Voucher scheme. This provides significant incentives for companies developing treatments for diseases like dengue. GEN-Y Biologics is advised it can garner several PRVs on successful approval of the dengue treatment mAb’s.

From the investor perspective, the dengue portfolio opportunity can be summarised as below

Dengue Portfolio - A remarkable investment opportunity

Dengue development to date has been driven by non-dilutive investment.

Huge market opportunity with major unmet needs driving strong demand.

Convincing proof of concept research underpinning a breakthrough in efficacy and a new paradigm in patient care.

High degree of confidence the product will qualify for substantial financial incentives through US FDA Priority Review Voucher program.

Modest investment required to accelerate development.

Development of a range of products with early sales from initial point of care diagnostic followed by landmark therapeutic and prophylaxis.

Contact Details

If you would like to learn more about investment opportunities in GEN-Y Biologics, we would be like to hear from you.
Please send an mail to Dr Graham at our office in Singapore.